Latest News

As the Australian market experiences fluctuations with sectors like real estate showing resilience and others lagging, investors are keenly observing the Reserve Bank of Australia's decisions and their impact on indices. In such a dynamic environment, dividend stocks can offer stability and income potential, making them an attractive option for those looking to bolster their portfolios amidst market uncertainties.

As the Australian market navigates a period of uncertainty, with recent RBA decisions and sector fluctuations impacting investor sentiment, attention is increasingly turning towards growth companies with high insider ownership. In such an environment, stocks where insiders hold significant stakes can often signal confidence in the company's long-term prospects, making them intriguing considerations for investors seeking stability and potential growth.

In the current Australian market landscape, recent events such as the Reserve Bank of Australia's decision to hold interest rates steady have led to mixed reactions, with major indices experiencing fluctuations and sectors like real estate showing some resilience. Amidst these conditions, identifying undervalued stocks can be a strategic approach for investors seeking opportunities that may offer potential upside when market sentiments shift.

The Australian market recently experienced a brief surge following the Reserve Bank of Australia's decision to hold interest rates steady, though it settled into a slightly negative territory by the day's end. In such fluctuating conditions, identifying promising investments requires a keen eye for companies with strong financial foundations. Penny stocks, although an older term, remain relevant as they often represent smaller or newer companies that can offer unique opportunities for growth...

Enterprise Financial Services Corp's ( NASDAQ:EFSC ) dividend will be increasing from last year's payment of the same...

Key Insights Significant insider control over RLX Technology implies vested interests in company growth A total of 4...

On 4 December 2025, BioLife Solutions’ CFO and 10% owner Troy Wichterman sold 30,000 shares at an average US$25.72, raising about US$771,600 and leaving him with 152,769 shares. The sale comes shortly after BioLife reported Q3 2025 results that beat revenue and EPS forecasts and highlighted strong cell processing momentum and expansion investments. Next, we’ll assess how this insider selling, alongside stronger cell processing performance, may shape BioLife Solutions’ existing investment...

AECOM ( NYSE:ACM ) has announced that it will be increasing its dividend from last year's comparable payment on the...

Ascendis Pharma (NasdaqGS:ASND) just told investors the FDA has tagged its latest TransCon CNP filing as a major amendment, pushing the decision deadline to February 28, 2026, and subtly reshaping expectations for potential approval. See our latest analysis for Ascendis Pharma. The update lands after a strong run, with Ascendis Pharma’s year to date share price return of around 50% and 1 year total shareholder return of about 56%. This suggests momentum is still building as investors reassess...

In recent weeks, CRISPR Therapeutics has drawn fresh attention as it advances its CRISPR-based gene-editing pipeline, including early clinical work on CTX310 for lowering LDL cholesterol and triglycerides and ongoing commercialization of its approved therapy Casgevy for blood disorders. What stands out is how early progress with CTX310, alongside revised earnings expectations and sustained institutional interest, is beginning to reshape perceptions of CRISPR Therapeutics’ long-term role in...

Upbound Group, Inc. recently confirmed that its Board of Directors approved a first-quarter 2026 quarterly cash dividend of US$0.39 per share, payable on January 6, 2026, to shareholders of record on December 17, 2025. This continued dividend commitment, alongside the earlier refinancing of the company’s term loan to enhance liquidity and extend its maturity, signals a focus on maintaining financial flexibility while returning cash to shareholders. We’ll now explore how the refreshed term...

In early December 2025, BofA Securities downgraded PROCEPT BioRobotics from Buy to Neutral, citing slower utilization growth and decelerating system sales for its Aquablation technology amid tighter hospital capital budgets. The report still emphasized PROCEPT’s sizable market opportunity and financial flexibility, highlighting a tension between near-term growth concerns and longer-term adoption potential for Aquablation in benign prostatic hyperplasia. We’ll now examine how this slowdown in...

DPM Metals Inc. recently reported its first Mineral Resource Estimates for the Dumitru Potok, Rakita North and Frasen prospects in eastern Serbia, outlining 84.4 million tonnes of inferred resources at 0.97 g/t gold and 1.02% copper, close to planned Coka Rakita infrastructure. These new resources, together with the Coka Rakita feasibility study confirming a high-margin underground mine underpinned by DPM’s long-standing Serbian presence, point to a potential district-scale gold-copper hub...

Healthpeak Properties, Inc. recently released an updated investor presentation and shifted to paying monthly dividends, while outlining plans to monetize up to US$1.00 billion of its outpatient medical office portfolio to fund development, acquisitions, and share repurchases. This combination of a clearer investor roadmap, a higher and more frequent dividend, and recycling capital from outpatient assets highlights a sharpened focus on capital allocation and income consistency for...

GEO Group (GEO) has been grinding through a tricky year, and the stock’s recent bounce contrasts sharply with its weak past 3 months and deep year to date drawdown. See our latest analysis for GEO Group. Over the past few weeks, a 10.91% 1 month share price return to $16.78 has only partially offset GEO Group’s sharp year to date share price loss, while its 3 year total shareholder return still looks robust, suggesting sentiment is stabilising after a tough stretch. If GEO’s rebound has you...

Arthur J. Gallagher (AJG) has been slipping lately, with the stock down over the past month and past 3 months, even as revenue and net income continue to grow at a healthy double digit clip. See our latest analysis for Arthur J. Gallagher. Zooming out, that recent weakness sits against a share price of $237.85 and a solid backdrop, with the 5 year total shareholder return of 108.16 percent still signaling long term momentum, even as shorter term share price returns cool. If AJG's pullback has...

As we approach the end of 2025, Canadian markets have shown strong performance with the TSX delivering double-digit gains. Amidst this backdrop, investors are closely monitoring central bank meetings and employment data while anticipating a potential Santa Claus rally. Although the term 'penny stocks' might seem outdated, these smaller or newer companies can offer substantial growth opportunities when they boast solid financials and fundamentals.

NovoCure has announced that CEO and Director Ashley Cordova resigned effective November 30, 2025, with President Frank Leonard stepping into the Chief Executive Officer role from December 1, 2025, while Executive Chairman William F. Doyle represented the company at the Piper Sandler Healthcare Conference shortly thereafter. The leadership handover to Leonard, a long-time internal executive who has overseen global operations and innovation, suggests continuity in both commercial execution and...

Zai Lab Limited recently dosed the first participant in a global Phase 1/1b trial of ZL-1503, its internally discovered IL-13/IL-31R bispecific antibody for moderate-to-severe atopic dermatitis, and secured 2025 National Reimbursement Drug List renewal in China for VYVGART, NUZYRA, and ZEJULA. Together, these developments highlight Zai Lab’s efforts to build proprietary immunology assets while preserving broad reimbursement for key in-licensed therapies in China’s healthcare system. We’ll...

Over recent weeks, Vertiv Holdings has expanded its AI-focused data center capabilities through the completed US$1.00 billion PurgeRite acquisition, a power-systems collaboration with Nvidia for future 800V DC facilities, and a sizeable quarterly dividend increase announced in mid-November. These moves strengthen Vertiv’s role in high-density, liquid-cooled AI infrastructure and grid technology just as global data center power needs are projected to more than double by decade-end. Next,...

Solventum (SOLV) has quietly put together a solid run, with the stock up around 25% this year and roughly 16% over the past 3 months, catching more investor attention. See our latest analysis for Solventum. That move has been driven more by a re-rating than a one off headline. The latest 1 month share price return of about 15% has added to already strong year to date momentum, even after a recent pullback to around $82.60. If Solventum’s recent run has you rethinking your healthcare exposure,...

Enphase Energy (ENPH) just started shipping its new IQ EV Charger 2 across the U.S. and Canada, a move that quietly pushes the stock’s story beyond solar into mainstream home and commercial EV charging. See our latest analysis for Enphase Energy. The new IQ EV Charger 2 and recent PowerMatch launch in Europe arrive against a tough backdrop, with the 1 year total shareholder return down sharply and the year to date share price return still deeply negative. However, the strong 7 day share price...

Sunstone Hotel Investors (SHO) has quietly slid about 24% over the past year, even as its annual revenue and net income have both grown. That disconnect naturally raises a valuation question for patient income investors. See our latest analysis for Sunstone Hotel Investors. Despite a modest 1 day share price return of minus 0.22%, the bigger story is the roughly 24% year to date share price decline and similarly weak 1 year total shareholder return. This suggests sentiment has cooled even as...

In early December 2025, Somnigroup International board member Simon Dyer disclosed a Form 4 insider purchase of 32,000 shares, worth about US$3.00 million, signaling his personal commitment to the company. This sizeable insider buying, coming soon after Somnigroup’s proposed all-stock acquisition of Leggett & Platt, highlights internal confidence in the combined group’s long-term direction. Next, we’ll explore how Simon Dyer’s sizeable insider buying shapes Somnigroup International’s...